{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:56:44Z","timestamp":1791284204533,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003035","name":"Aase og Ejnar Danielsens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008262","name":"Harboefonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008262","id-type":"DOI","asserted-by":"publisher"}]},{"name":"L\u00e6ge Sofus Carl Emil Friis og hustru Olga Doris Friis Mindelegat"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"DOI":"10.1038\/s41416-026-03633-5","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:46:57Z","timestamp":1791283617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical significance of circulating macrophage markers across different stages of prostate cancer: highlighting soluble CD163"],"prefix":"10.1038","author":[{"given":"Emma B.","family":"Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian W.","family":"Antonsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads R.","family":"Jochumsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8179-5989","authenticated-orcid":false,"given":"Paul V.","family":"Salachan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Bouchelouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7476-671X","authenticated-orcid":false,"given":"Torben F.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palle J. S.","family":"Osther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed H.","family":"Zedan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1519-9185","authenticated-orcid":false,"given":"Michael","family":"Borre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger J.","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4902-5490","authenticated-orcid":false,"given":"Karina D.","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"3633_CR1","doi-asserted-by":"publisher","first-page":"T179","DOI":"10.1530\/ERC-16-0422","volume":"23","author":"I Coutinho","year":"2016","unstructured":"Coutinho I, Day TK, Tilley WD, Selth LA. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocr Relat Cancer. 2016;23:T179\u2013t97.","journal-title":"Endocr Relat Cancer"},{"key":"3633_CR2","doi-asserted-by":"publisher","first-page":"e241970","DOI":"10.1001\/jamanetworkopen.2024.1970","volume":"7","author":"MW Schoen","year":"2024","unstructured":"Schoen MW, Montgomery RB, Owens L, Khan S, Sanfilippo KM, Etzioni RB. Survival in patients with de novo metastatic prostate cancer. JAMA Network Open. 2024;7:e241970.","journal-title":"JAMA Network Open"},{"key":"3633_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104384","volume":"30","author":"S Zhang","year":"2025","unstructured":"Zhang S, Zhang T, Kinsella GK, Curtin JF. A review of the efficacy of prostate cancer therapies against castration-resistant prostate cancer. Drug Discov Today. 2025;30:104384.","journal-title":"Drug Discov Today"},{"key":"3633_CR4","unstructured":"EAU Guidelines: Edn. presented at the EAU Annual Congress Madrid 2025. ISBN 978-94-92671-29-5."},{"key":"3633_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41568-020-0267-9","volume":"20","author":"JS de Bono","year":"2020","unstructured":"de Bono JS, Guo C, Gurel B, De Marzo AM, Sfanos KS, Mani RS, et al. Prostate carcinogenesis: inflammatory storms. Nat Rev Cancer. 2020;20:455\u201369.","journal-title":"Nat Rev Cancer"},{"key":"3633_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/path.5757","volume":"255","author":"LB Andersen","year":"2021","unstructured":"Andersen LB, N\u00f8rgaard M, Rasmussen M, Freds\u00f8e J, Borre M, Ulh\u00f8i BP, et al. Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors. J Pathol. 2021;255:155\u201365.","journal-title":"J Pathol"},{"key":"3633_CR7","first-page":"523","volume":"3","author":"K Gollapudi","year":"2013","unstructured":"Gollapudi K, Galet C, Grogan T, Zhang H, Said JW, Huang J, et al. Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. Am J Cancer Res. 2013;3:523\u20139.","journal-title":"Am J Cancer Res"},{"key":"3633_CR8","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/s41379-018-0083-x","volume":"31","author":"HB Kaur","year":"2018","unstructured":"Kaur HB, Guedes LB, Lu J, Maldonado L, Reitz L, Barber JR, et al. Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer. Mod Pathol. 2018;31:1539\u201352.","journal-title":"Mod Pathol"},{"key":"3633_CR9","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/modpathol.2012.164","volume":"26","author":"S Davidsson","year":"2013","unstructured":"Davidsson S, Ohlson AL, Andersson SO, Fall K, Meisner A, Fiorentino M, et al. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer. Mod Pathol. 2013;26:448\u201355.","journal-title":"Mod Pathol"},{"key":"3633_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/486798","volume":"2014","author":"M Lanciotti","year":"2014","unstructured":"Lanciotti M, Masieri L, Raspollini MR, Minervini A, Mari A, Comito G, et al. The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy. Biomed Res Int. 2014;2014:486798.","journal-title":"Biomed Res Int"},{"key":"3633_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/srep15651","volume":"5","author":"M Lundholm","year":"2015","unstructured":"Lundholm M, H\u00e4ggl\u00f6f C, Wikberg ML, Stattin P, Egevad L, Bergh A, et al. Secreted factors from colorectal and prostate cancer cells skew the immune response in opposite directions. Sci Rep. 2015;5:15651.","journal-title":"Sci Rep"},{"key":"3633_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/pros.23742","volume":"79","author":"A Erlandsson","year":"2019","unstructured":"Erlandsson A, Carlsson J, Lundholm M, F\u00e4lt A, Andersson S-O, Andr\u00e9n O, et al. M2 macrophages and regulatory T cells in lethal prostate cancer. The Prostate. 2019;79:363\u20139.","journal-title":"The Prostate"},{"key":"3633_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02089-2","volume":"21","author":"J Liu","year":"2021","unstructured":"Liu J, Geng X, Hou J, Wu G. New insights into M1\/M2 macrophages: key modulators in cancer progression. Cancer Cell Int. 2021;21:389.","journal-title":"Cancer Cell Int"},{"key":"3633_CR14","doi-asserted-by":"publisher","first-page":"67.12","DOI":"10.4049\/jimmunol.198.Supp.67.12","volume":"198","author":"L Shi","year":"2017","unstructured":"Shi L, Bian Z, Liu Y. Dual role of SIRP\u03b1 in macrophage activation: inhibiting M1 while promoting M2 polarization via selectively activating SHP-1 and SHP-2 signal. J Immunol. 2017;198:67.12\u201367.12.","journal-title":"J Immunol"},{"key":"3633_CR15","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1111\/cas.14971","volume":"112","author":"N Koga","year":"2021","unstructured":"Koga N, Hu Q, Sakai A, Takada K, Nakanishi R, Hisamatsu Y, et al. Clinical significance of signal regulatory protein alpha (SIRP\u03b1) expression in esophageal squamous cell carcinoma. Cancer Science. 2021;112:3018\u201328.","journal-title":"Cancer Science"},{"key":"3633_CR16","doi-asserted-by":"publisher","first-page":"109.e11","DOI":"10.1016\/j.urolonc.2021.08.024","volume":"40","author":"Z Xu","year":"2022","unstructured":"Xu Z, Zeng H, Liu Z, Jin K, Chang Y, Wang Y, et al. Poor clinical outcomes and immunoevasive contexture in SIRP\u03b1(+) tumor-associated macrophages enriched muscle-invasive bladder cancer patients. Urol Oncol. 2022;40:109.e11\u2013e20.","journal-title":"Urol Oncol"},{"key":"3633_CR17","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3390\/biom12070937","volume":"12","author":"YV Vladimirova","year":"2022","unstructured":"Vladimirova YV, M\u00f8lmer MK, Antonsen KW, M\u00f8ller N, Rittig N, Nielsen MC, et al. A new serum macrophage checkpoint biomarker for innate immunotherapy: soluble signal-regulatory protein alpha (sSIRP\u03b1). Biomolecules. 2022;12:937.","journal-title":"Biomolecules"},{"key":"3633_CR18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1182\/blood.V99.1.378","volume":"99","author":"HJ M\u00f8ller","year":"2002","unstructured":"M\u00f8ller HJ, Peterslund NA, Graversen JH, Moestrup SK. Identification of the hemoglobin scavenger receptor\/CD163 as a natural soluble protein in plasma. Blood. 2002;99:378\u201380.","journal-title":"Blood"},{"key":"3633_CR19","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.3390\/ijms21165925","volume":"21","author":"D Krijgsman","year":"2020","unstructured":"Krijgsman D, De Vries NL, Andersen MN, Skovbo A, Tollenaar R, M\u00f8ller HJ, et al. CD163 as a biomarker in colorectal cancer: the expression on circulating monocytes and tumor-associated macrophages, and the soluble form in the blood. Int J Mol Sci. 2020;21:5925.","journal-title":"Int J Mol Sci"},{"key":"3633_CR20","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.3892\/ol.2017.6547","volume":"14","author":"D Ding","year":"2017","unstructured":"Ding D, Song Y, Yao Y, Zhang S. Preoperative serum macrophage activated biomarkers soluble mannose receptor (sMR) and soluble haemoglobin scavenger receptor (sCD163), as novel markers for the diagnosis and prognosis of gastric cancer. Oncol Lett. 2017;14:2982\u201390.","journal-title":"Oncol Lett"},{"key":"3633_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000349892","volume":"75","author":"JH No","year":"2013","unstructured":"No JH, Moon JM, Kim K, Kim YB. Prognostic significance of serum soluble CD163 level in patients with epithelial ovarian cancer. Gynecol Obstet Investig. 2013;75:263\u20137.","journal-title":"Gynecol Obstet Investig"},{"key":"3633_CR22","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3390\/diagnostics12020336","volume":"12","author":"S Davidsson","year":"2022","unstructured":"Davidsson S, Huotilainen S, Carlsson J, Sundqvist P. Soluble levels of CD163, PD-L1, and IL-10 in renal cell carcinoma patients. Diagnostics. 2022;12:336.","journal-title":"Diagnostics"},{"key":"3633_CR23","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3390\/cancers15051544","volume":"15","author":"N Aggerholm-Pedersen","year":"2023","unstructured":"Aggerholm-Pedersen N, Friis HN, Baad-Hansen T, M\u00f8ller HJ, Sandfeld-Paulsen B. Macrophage biomarkers sCD163 and sSIRP\u03b1 in serum predict mortality in sarcoma patients. Cancers. 2023;15:1544.","journal-title":"Cancers"},{"key":"3633_CR24","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1200\/JCO.2008.19.9919","volume":"27","author":"TO Jensen","year":"2009","unstructured":"Jensen TO, Schmidt H, M\u00f8ller HJ, H\u00f8yer M, Maniecki MB, Sjoegren P, et al. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I\/II melanoma. J Clin Oncol. 2009;27:3330\u20137.","journal-title":"J Clin Oncol"},{"key":"3633_CR25","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/clinchem\/hvac224","volume":"69","author":"M N\u00f8rgaard","year":"2023","unstructured":"N\u00f8rgaard M, Bjerre MT, Freds\u00f8e J, Vang S, Jensen JB, De Laere B, et al. Prognostic value of low-pass whole genome sequencing of circulating tumor DNA in metastatic castration-resistant prostate cancer. Clin Chem. 2023;69:386\u201398.","journal-title":"Clin Chem"},{"key":"3633_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-46323-5","volume":"13","author":"EB Hansen","year":"2023","unstructured":"Hansen EB, Karlsson Q, Merson S, Wakerell S, Rageevakumar R, Jensen JB, et al. Impact of germline DNA repair gene variants on prognosis and treatment of men with advanced prostate cancer. Sci Rep. 2023;13:19135.","journal-title":"Sci Rep"},{"key":"3633_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-43937-7","volume":"13","author":"AH Zedan","year":"2023","unstructured":"Zedan AH, Nederby L, Volmer LM, Madsen CV, S\u00f8rensen BE, Hansen TF. Natural killer cell activity in metastatic castration resistant prostate cancer patients treated with enzalutamide. Sci Rep. 2023;13:17144.","journal-title":"Sci Rep"},{"key":"3633_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-57101-7","volume":"10","author":"AH Zedan","year":"2020","unstructured":"Zedan AH, Osther PJS, Assenholt J, Madsen JS, Hansen TF. Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer. Sci Rep. 2020;10:227.","journal-title":"Sci Rep"},{"key":"3633_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00540-x","volume":"8","author":"M Rasmussen","year":"2024","unstructured":"Rasmussen M, Freds\u00f8e J, Salachan PV, Blanke MPL, Larsen SH, Ulh\u00f8i BP, et al. Stroma-specific gene expression signature identifies prostate cancer subtype with high recurrence risk. npj Precis Oncol. 2024;8:48.","journal-title":"npj Precis Oncol"},{"key":"3633_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-01009-3","volume":"14","author":"EB Hansen","year":"2022","unstructured":"Hansen EB, Freds\u00f8e J, Okholm TLH, Ulh\u00f8i BP, Klingenberg S, Jensen JB, et al. The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer. Genom Med. 2022;14:8.","journal-title":"Genom Med"},{"key":"3633_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36325-2","volume":"14","author":"T Hirz","year":"2023","unstructured":"Hirz T, Mei S, Sarkar H, Kfoury Y, Wu S, Verhoeven BM, et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun. 2023;14:663.","journal-title":"Nat Commun"},{"key":"3633_CR32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/path.70023","volume":"268","author":"ML Blanke","year":"2026","unstructured":"Blanke ML, Salachan PV, Georgsen JB, Freds\u00f8e J, Ulh\u00f8i B, Borre M, et al. Cancer-associated fibroblast subtypes in the tumor microenvironment of prostate cancer and associations to patient outcomes. J Pathol. 2026;268:413\u201327.","journal-title":"J Pathol"},{"key":"3633_CR33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/003655102760145852","volume":"62","author":"HJ M\u00f8ller","year":"2002","unstructured":"M\u00f8ller HJ, Hald K, Moestrup SK. Characterization of an enzyme-linked immunosorbent assay for soluble CD163. Scand J Clin Lab Investig. 2002;62:293\u20139.","journal-title":"Scand J Clin Lab Investig"},{"key":"3633_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/00365513.2011.626868","volume":"72","author":"HJ M\u00f8ller","year":"2012","unstructured":"M\u00f8ller HJ. Soluble CD163. Scand J Clin Lab Investig. 2012;72:1\u201313.","journal-title":"Scand J Clin Lab Investig"},{"key":"3633_CR35","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402\u201318.","journal-title":"J Clin Oncol"},{"key":"3633_CR36","unstructured":"Team RC R. A Language and Environment for Statistical Computing. 2023."},{"key":"3633_CR37","unstructured":"teamP. RStudio: Integrated Development Environment for R. Boston, MA: Posit Software, PBC; 2025."},{"key":"3633_CR38","doi-asserted-by":"publisher","first-page":"9067","DOI":"10.1200\/JCO.2004.01.0454","volume":"23","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005;23:9067\u201372.","journal-title":"J Clin Oncol"},{"key":"3633_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44255-2","volume":"14","author":"X Xing","year":"2023","unstructured":"Xing X, Cai L, Ouyang J, Wang F, Li Z, Liu M, et al. Proteomics-driven noninvasive screening of circulating serum protein panels for the early diagnosis of hepatocellular carcinoma. Nat Commun. 2023;14:8392.","journal-title":"Nat Commun"},{"key":"3633_CR40","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00262-022-03266-6","volume":"72","author":"KM Lauridsen","year":"2023","unstructured":"Lauridsen KM, Hokland M, Al-Karradi S, M\u00f8ller HJ, Donskov F, Andersen MN. Soluble CD163: a novel independent prognostic biomarker in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2023;72:461\u201373.","journal-title":"Cancer Immunol Immunother"},{"key":"3633_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-2053-6","volume":"17","author":"X Ruiz-Plazas","year":"2019","unstructured":"Ruiz-Plazas X, Rodr\u00edguez-Gallego E, Alves M, Altuna-Coy A, Lozano-Bartolom\u00e9 J, Portero-Otin M, et al. Biofluid quantification of TWEAK\/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness. J Transl Med. 2019;17:307.","journal-title":"J Transl Med"},{"key":"3633_CR42","doi-asserted-by":"publisher","first-page":"5304","DOI":"10.1182\/bloodadvances.2023010052","volume":"7","author":"A Nikkarinen","year":"2023","unstructured":"Nikkarinen A, Lokhande L, Amini RM, Jerkeman M, Porwit A, Molin D, et al. Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma. Blood Adv. 2023;7:5304\u201313.","journal-title":"Blood Adv"},{"key":"3633_CR43","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1093\/annonc\/mdy406","volume":"29","author":"AJ Armstrong","year":"2018","unstructured":"Armstrong AJ, Lin P, Higano CS, Sternberg CN, Sonpavde G, Tombal B, et al. Development and validation of a prognostic model for overall survival in chemotherapy-na\u00efve men with metastatic castration-resistant prostate cancer. Ann Oncol. 2018;29:2200\u20137.","journal-title":"Ann Oncol"},{"key":"3633_CR44","doi-asserted-by":"publisher","first-page":"401.e11","DOI":"10.1016\/j.urolonc.2018.06.004","volume":"36","author":"SY Choi","year":"2018","unstructured":"Choi SY, Ryu J, You D, Jeong IG, Hong JH, Ahn H, et al. Prognostic factors of oncologic outcomes in metastatic chemotherapy-na\u00efve castration-resistant prostate cancer treated with enzalutamide in actual clinical practice in East Asia. Urol Oncol. 2018;36:401.e11\u2013e18.","journal-title":"Urol Oncol"},{"key":"3633_CR45","first-page":"587","volume":"8","author":"H Murata","year":"2018","unstructured":"Murata H, Koyama K, Takezawa Y, Nishigaki Y. Baseline neutrophil-to-lymphocyte ratio predicts the prognosis of castration-resistant prostate cancer treated with abiraterone acetate. Mol Clin Oncol. 2018;8:587\u201391.","journal-title":"Mol Clin Oncol"},{"key":"3633_CR46","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.euo.2019.01.009","volume":"3","author":"T Loubersac","year":"2020","unstructured":"Loubersac T, Nguile-Makao M, Pouliot F, Fradet V, Toren P. Neutrophil-to-lymphocyte ratio as a predictive marker of response to abiraterone acetate: a retrospective analysis of the COU302 study. Eur Urol Oncol. 2020;3:298\u2013305.","journal-title":"Eur Urol Oncol"},{"key":"3633_CR47","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41391-020-0209-3","volume":"23","author":"Y Guan","year":"2020","unstructured":"Guan Y, Xiong H, Feng Y, Liao G, Tong T, Pang J. Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. Prostate Cancer Prostatic Dis. 2020;23:220\u201331.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3633_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12593-z","volume":"24","author":"Z Wang","year":"2024","unstructured":"Wang Z, Liu H, Zhu Q, Chen J, Zhao J, Zeng H. Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer. BMC Cancer. 2024;24:817.","journal-title":"BMC Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03633-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03633-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03633-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:47:01Z","timestamp":1791283621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03633-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":48,"alternative-id":["3633"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03633-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Holger Jon M\u00f8ller is cofounder and shareholder in Spica Therapeutics.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All research was carried out in accordance with relevant regulations and guidelines and adheres to the principles of the Declaration of Helsinki. Written informed consent was obtained from all patients prior to their donation of blood samples for a research biobank (approved by The Central Denmark Region Committees on Health Research Ethics (#2000\/0299, #1-10-72-139-15, #1-10-72-262-21), The Southern Denmark Region Committees on Health Research Ethics (S-20110102, S-20130099, S-20160029), and The Danish Data Protection Agency (#1-16-02-419-25, #1-16-02-158-20, #1-16-02-366-15). The present study was approved by the The Central Denmark Region Committees on Health Research Ethics (#1-10-72-157-23), who waived the requirement for patient consent, as (1) the new analyses were considered not to pose any health risk or other disadvantages to the participants and (2) the study did not involve any methods, which are considered comprehensive investigation (e.g. genomic profiling), but solely the measurement of the two soluble macrophage markers sSIRP\u03b1 and sCD163 in serum.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}